Van Helsing

Amable recordatorio: NO EXISTE LA ESPECIALIDAD DE MEDICINA ESTÉTICA... La Especialidad es DERMATOLOGIA o CIRUGIA PLASTICA Y ESTETICA.. La medicina estetica son cursillos y diplomados... o sea pinchis nada...

Important EHA2026 data in UHR LBCL 👇 In this large international retrospective cohort of 1,923 ultra–high-risk LBCL pts, HD-MTX did not reduce CNS relapse. What makes this clinically relevant: baseline imbalance reflects real-world practice—HD-MTX was preferentially used in pts with renal/adrenal, testicular, ≥3 extranodal sites, and many also received IT MTX during chemo (~50% in HD-MTX arm). Yet, despite this intensified “current CNS prophylaxis strategy,” CNS relapse remained similar: Any CNSr: 9.3% vs 8.1% Isolated CNSr: 5.9% vs 5.7% This challenges the routine reflex of adding HD-MTX for CNS prophylaxis in UHR LBCL. The next key question: Will this still hold true in the Pola-R-CHP era? although POLARIX - did not show lower CNS relapse #EHA2026 #Lymphoma #DLBCL #CNSRelapse #HDMTX #PolaRCHP #Hematology @Charanpreet_14 @DrGPrakash @EHA_Hematology

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management #lymsm |American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

For patients starting Lenalidomide, thromboprophylaxis should be guided by the IMWG and NCCN recommendations using validated risk scores such as IMPEDE VTE Score and SAVED Score. 🩸 All patients receiving lenalidomide-based therapy require VTE risk assessment. 🟢 Low Risk ➡️ No or minimal risk factors ➡️ Aspirin 81–100 mg PO daily 🟠 Intermediate/High Risk ➡️ Any of the following: • Prior VTE • Obesity • Immobility • Central venous catheter • High-dose dexamethasone • Anthracycline-containing therapy • Use of erythropoiesis-stimulating agents • Active infection • Cardiac disease • Recent surgery • Known thrombophilia ➡️ Preferred prophylaxis: • Apixaban 2.5 mg PO BID • Rivaroxaban 10 mg PO daily • Enoxaparin 40 mg SC daily • Warfarin (INR 2–3) if other options are unsuitable 🔴 Very High Risk ➡️ Recent VTE or strong thrombophilia ➡️ Therapeutic anticoagulation may be required. ⏳ Duration ➡️ Continue while receiving lenalidomide-based therapy or until risk factors resolve. ⚠️ Hold prophylaxis if: • Platelets <50 × 10⁹/L (individualize) • Active bleeding • Severe coagulopathy 💎 Clinical Pearl Lenalidomide + dexamethasone substantially increases VTE risk; aspirin is acceptable only for truly low-risk patients. 📚 Key Guidelines 📌 National Comprehensive Cancer Network Multiple Myeloma Guidelines 📌 International Myeloma Working Group recommendations 📌 Sanfilippo KM et al. J Clin Oncol. 2019 (IMPEDE VTE) #MultipleMyeloma #Lenalidomide #Revlimid #VTE #Thromboprophylaxis #IMPEDE #SAVED #Hematology

INTENSIVE CHEMOTHERAPY IN COMBINATION WITH QUIZARTINIB VERSUS MIDOSTAURIN FOR FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA: A MULTICENTER COHORT STUDY library.ehaweb.org/eha/2026/eha-2… #AML #leusm #EHA26

A great oncologist once told me “the purpose of the heart is to pump the chemo to the cancer”

Happy Mother's Day! Stem cell in Spanish is "célula madre" which I find just perfect.

Embiid pulled up to game 7 as the LeBron “down 3-1” meme 😭

We recently discussed t(11;14), t(4;14), and t(14;16). Today—let’s simplify what matters most at the bedside: 👉 t(11;14) = “Leaky myeloma” 💧 👉 t(14;16) = “Sticky myeloma” 🧲 Yes… leaky vs sticky. 💧 t(11;14) — LEAKY    •   CD56 negative → no adhesion    •   Cells don’t stay in marrow → spill into blood    •   PB involvement, EMD more common 🧠 Think: No glue → no home → they wander 🎯 Biology: BCL-2 dependent → Target the protein (venetoclax) 🧲 t(14;16) — STICKY    •   MAF → adhesion molecules + IL-6 signaling    •   Early disease: locked in marrow niche    •   Protected, hidden, therapy-resistant 🧠 Think: Glued in place… safe for now 💥 Then evolution happens: → Lose niche dependence → Break out → aggressive EMD 🎯 The big difference:    •   t(11;14) → escapes early    •   t(14;16) → escapes late… and worse ⚡ Clinical translation:    •   Leaky → target the vulnerability (BCL-2)    •   Sticky → disrupt the environment + multi-agent therapy 🧠 If you remember one thing: 💧 If it leaks → shut the valve 🧲 If it sticks → break the niche ✍️ Dr Fun + G #myeloma #hemetwitter

Adding blinatumomab and inotuzumab to hyperCVAD in younger B-cell #ALL improves EFS from 66% to 89% doi.org/10.1002/ajh.70… @AjHematology @UTMDAnderson

How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide ashpublications.org/blood/article-…

How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide | Blood | American Society of Hematology ashpublications.org/blood/article/…

Acute GVHD is not acute inflammation. It is apoptosis → crypt loss. Case Day 60 post transplant High-volume diarrhea CMV- C diff - ID - 👉 Likely acute GI GVHD → The crypt (stem cell niche) is under attack by activated T cells + cytokines Step 1 — Endoscopy (pattern) • Diffuse vs focal • Ulcer present or not 👉 Diffuse + intact → think GVHD 👉 Focal or ulcer → prove infection (CMV first) Step 2 — Biopsy (mechanism) • Apoptosis → crypt loss → GVHD or MMF • Dense inflammation → infection/colitis • Inclusion (IHC) → CMV 👉 GVHD = epithelial cell death, not inflammation Step 3 — Context • On Cellcept (MMF)? 👉 Can mimic GVHD Bottom line Read the scope Read the crypt Check IHC (CMV) Remember the drug Few cells ≠ low inflammation #GVHD #Hemetwitter

#weekend_review #AML #leusm 1/ 🚨 AML in 2026 is no longer “one-size-fits-all.” We’ve moved from static risk → dynamic, MRD-driven, biology-informed care. Here’s what’s changed 👇 #AML #leusm

🧠 Myeloma neuropathy—keep it simple. We often treat it like one disease. It’s not. 👉 4 phenotypes. 5 common mistakes. 🔥 Toxic (Velcade) 🧬 Amyloid ⚡ POEMS 🦴 Mechanical Same symptom. Very different biology. Miss the phenotype → wrong treatment. “Neuropathy is not a diagnosis in myeloma. It’s a phenotype.” Dr Fun + G

PETHEMA presenta el protocolo LAL-2025 🧬
Y marca un hito: por fin contamos con un protocolo totalmente asistencial y actualizado para la leucemia linfoblástica aguda en adultos. 👇

@edurcorantes Pero no nos dejes así, presume nos bien qué fue.

@DarrylRMFC_ @JuanCaNH95

Give me Elche and racing Santander or I retire 😂

IACH News of the Week • April 7, 2026 • Highlights post-EBMT 2026 (52nd). #EBMT26 was convened in Madrid (Spain) from the 22nd to the 25th of March 2026. @Mohty_EBMT @TheIACH @TheEBMT Here are some key points from some sessions: iach.org/news-of-the-we…

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial @BloodPortfolio ashpublications.org/blood/article/…